Business
Non-Binding Proposal to Acquire TheraCryf’s Assets
TheraCryf plc announced it received a conditional, non-binding proposal to acquire its lead neuropsychiatry assets, the Orexin-1 and dopamine transporter programmes, but the Board unanimously rejected it as it did not reflect the assets' value or future commercial potential, particularly the Orexin-1 programme which is fully funded to Phase 1 clinical study by Q4 2026 and targets the US$42 billion addiction market. The company is confident in its assets' value and strategic importance, noting recent industry transactions, including an acquisition for up to US$7.8 billion, as validation of the orexin system's potential. Disclaimer*
About this update from Theracryf Plc
14 April 2026 TheraCryf plc ("TheraCryf", the "Company" or the "Group") Non-Binding Indicative Proposal to Acquire TheraCryf's Lead Neuropsychiatry Assets Received The Board has rejected the proposal on the basis that it does not reflect the value or future commercial potential of the assets, and is not in the best interests of shareholders TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, announces that it received a conditional, non-binding, indicative proposal regarding the potential acquisition of TheraCryf's lead neuropsychiatry assets, namely the Orexin-1 ("Ox-1") and dopamine transporter ("DAT") programmes (the "Indicative Proposal"). Following careful consideration, the Board unanimously concluded that the Indicative Proposal did not reflect the current or future value of the assets and was therefore not considered to be in the best interests of the Company and its shareholders. Accordingly, the Board rejected the Indicative Proposal and has terminated these recent discussions. The Board is confident in the value and strategic importance of its neuropsychiatry programmes, the most advanced of which is an Ox-1 receptor blocker being developed for addiction, a growing market worth US$42 billion¹. The Ox-1 programme, which is fully funded to generate all data required to support an application to conduct a Phase 1 clinical study by Q4 2026, represents a significant commercial opportunity to deliver long-term value for shareholders. Dr Huw Jones, Chief Executive Officer of TheraCryf, commented: "After detailed consideration by our Board, we have concluded that the Indicative Proposal did not reflect the value of our assets nor their significant future commercial potential. Given the excellent progress towards the clinic of the Orexin-1 programme, which represents a major value inflection point for the Company, the Board is confident that the best route to delivering significant shareholder value is to continue to develop our lead assets and we therefore rejected the proposal. It is encouraging to note that our assets are receiving commercial attention, in line with other modulators of the orexin system, such as the transaction recently announced to acquire a clinical-stage orexin company in a dif...